Novi Zeland - engleski - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - coal tar solution 1%;  ;  ; pine tar 1%;  ; salicylic acid 2%;  ;  ; undecenoic acid monoethanolamide 1%; coal tar solution 1%; pine tar 1%; salicylic acid 2%; coal tar solution 1%; pine tar 1%; salicylic acid 2% - shampoo - active: coal tar solution 1%     pine tar 1%   salicylic acid 2%     undecenoic acid monoethanolamide 1% excipient: benzyl alcohol disodium cocoamphodiacetate laurilbetaine lavender extract purified water sodium lauril trioxyethylene sulfate active: coal tar solution 1% pine tar 1% salicylic acid 2% excipient: benzyl alcohol disodium cocoamphodiacetate laurilbetaine lauromacrogol 1150 lauromacrogol 200 o/a 10920 baniadas purified water sodium laureth sulfate trolamine active: coal tar solution 1% pine tar 1% salicylic acid 2% excipient: baniaddas fragrance 175454 benzyl alcohol disodium cocoamphodiacetate laurilbetaine lauromacrogol 1150 lauromacrogol 200 purified water sodium laureth sulfate trolamine - relieves itching scalp and reduce inflammation. it relieves symptoms of seborrhoeic dermatitis (scaling and flaking scalp), eczema and psoriasis of the scalp.

Novi Zeland - engleski - Medsafe (Medicines Safety Authority)

ebos group ltd - lanolin 0.6% ((anhydrous) as viscolan); light liquid paraffin 8.75%{relative}; liquid paraffin 7.15%{relative}; lanolin oil 0.58%{relative}; liquid paraffin 15.86%{relative} - lotion - active: lanolin 0.6% ((anhydrous) as viscolan) light liquid paraffin 8.75%{relative} liquid paraffin 7.15%{relative} excipient: carbomer 934 docusate sodium glyceryl monostearate lauromacrogol 400 macrogol 200 macrogol stearate 2000 methyl hydroxybenzoate perfume givaudan pa-1614 (w6300-3) propyl hydroxybenzoate propylene glycol purified water trolamine active: lanolin oil 0.58%{relative} liquid paraffin 15.86%{relative} excipient: carbomer 934 docusate sodium glyceryl monostearate lauromacrogol 400 macrogol stearate 2000 methyl hydroxybenzoate n-(3-chloroallyl)hexaminium chloride perfume w6300-3 polyethylene glycol 400 dilaurate propyl hydroxybenzoate propylene glycol purified water trolamine

Novi Zeland - engleski - Medsafe (Medicines Safety Authority)

boucher & muir (new zealand) limited t/a bnm group - coal tar solution 4.25%{relative} (81-86% ethanol); salicylic acid 2%{relative};  ;  ;   - shampoo - active: coal tar solution 4.25%{relative} (81-86% ethanol) salicylic acid 2%{relative}       excipient: benzalkonium chloride ethanol lauromacrogol 1150 lauromacrogol 200 purified water sodium edetate

Novi Zeland - engleski - Medsafe (Medicines Safety Authority)

haleon new zealand ulc - benzoyl peroxide 10% (+ overage of 19.95% =11.995%);  ;  ; benzoyl peroxide 10%{relative} (+ overage of 19.95% =11.995%) - topical gel - 10 % - active: benzoyl peroxide 10% (+ overage of 19.95% =11.995%)     excipient: citric acid monohydrate denatonium benzoate ethanol hypromellose lauromacrogol 200 perfume/fragrance alpine 6565a saponite tert-butyl alcohol water active: benzoyl peroxide 10%{relative} (+ overage of 19.95% =11.995%) excipient: citric acid ethanol hypromellose colloidal aluminium magnesium silicate lauromacrogol 200 perfume/fragrance alpine 6565a water

Novi Zeland - engleski - Medsafe (Medicines Safety Authority)

haleon new zealand ulc - benzoyl peroxide 5% (+ 19.98% overage = 5.999%);  ;  ; benzoyl peroxide 5%{relative} (+ 19.98% overage = 5.999%) - topical gel - 5 % - active: benzoyl peroxide 5% (+ 19.98% overage = 5.999%)     excipient: citric acid monohydrate denatonium benzoate ethanol hypromellose lauromacrogol 200 perfume/fragrance alpine 6565a saponite tert-butyl alcohol water active: benzoyl peroxide 5%{relative} (+ 19.98% overage = 5.999%) excipient: citric acid ethanol hypromellose colloidal aluminium magnesium silicate lauromacrogol 200 perfume/fragrance alpine 6565a water

Novi Zeland - engleski - Medsafe (Medicines Safety Authority)

stafford-miller (nz) limited - permethrin 1%{relative} (as 1.05%w/w of 95% concentrate solution);   - shampoo - 1% w/v - active: permethrin 1%{relative} (as 1.05%w/w of 95% concentrate solution)   excipient: cetyl alcohol citric acid isopropyl alcohol laurildimethylamine oxide lauromacrogol 1150 lauromacrogol 200 liquid paraffin fragrance purified water trolamine laurilsulfate

Novi Zeland - engleski - Medsafe (Medicines Safety Authority)

unilever australasia division of unilever new zealand limited - pyrithione zinc 0.98%{relative} - shampoo - 1% w/w - active: pyrithione zinc 0.98%{relative} excipient: 1,5-pentanediol carbomer citric acid cocamidopropyl betaine dimethiconol dimeticone ethylene glycol distearate glycerol glydant guar hydroxypropyltrimonium chloride sodium laureth sulfate / sodium c12-13 pareth sulfate lauromacrogol 1150 lauromacrogol 200 macrogols magnesium chloride magnesium nitrate methyl hydroxybenzoate methylchloroisothiazolinone and methylisothiazolinone milk, fat free peg-40 castor oil persea americana poloxamer 407 ppg-12-buteth-16 sodium benzoate sodium chloride sodium hydroxide sodium laureth sulfate sodium polynaphthalenesulfonate triethanolamine dodecylbenzenesulfonate trolamine sulfate water xanthan gum zinc sulfate

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

ascend laboratories, llc - finasteride (unii: 57gno57u7g) (finasteride - unii:57gno57u7g) - finasteride 1 mg - finasteride tablets is indicated for the treatment of male pattern hair loss (androgenetic alopecia) in men only . efficacy in bitemporal recession has not been established. finasteride tablets is not indicated for use in women. finasteride tablets is contraindicated in the following: - pregnancy. finasteride use is contraindicated in women when they are or may potentially be pregnant. because of the ability of type ii 5α-reductase inhibitors to inhibit the conversion of testosterone to 5α-dihydrotestosterone (dht), finasteride may cause abnormalities of the external genitalia of a male fetus of a pregnant woman who receives finasteride. if this drug is used during pregnancy, or if pregnancy occurs while taking this drug, the pregnant woman should be apprised of the potential hazard to the male fetus.  [ see  warnings  and  precautions   (5.1),  use  in  specific  populations  (8.1),  how  supplied / storage  and  handling  ( 16 )  and  patient   counseling  information  (17).]  in  female  rats,  low  doses